Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-1,41%
1 076,13
-15,38
-1,41%
—1 091,511 090,401 090,401 073,69——
SIXC
Communications
SIXC
Communications
SIXC
-0,55%
606,74
-3,37
-0,55%
—610,11610,11610,29606,17——
SIXE
Energy
SIXE
Energy
SIXE
+0,88%
1 248,82
+10,84
+0,88%
—1 237,981 237,831 252,411 225,03——
SIXI
Industrials
SIXI
Industrials
SIXI
-1,17%
1 724,36
-20,35
-1,17%
—1 744,711 740,951 747,291 721,57——
SIXM
Financials
SIXM
Financials
SIXM
-0,72%
635,59
-4,59
-0,72%
—640,18639,92643,19634,73——
SIXR
Staples
SIXR
Staples
SIXR
-0,76%
843,15
-6,43
-0,76%
—849,58845,27851,68839,47——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,55%
216,29
-1,19
-0,55%
—217,48217,48218,16215,51——
SIXT
Technology
SIXT
Technology
SIXT
+0,08%
3 263,41
+2,72
+0,08%
—3 260,693 273,363 287,813 240,78——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,34%
939,24
-3,21
-0,34%
—942,45939,39948,80933,98——
SIXV
Health care
SIXV
Health care
SIXV
-0,29%
1 462,56
-4,24
-0,29%
—1 466,801 464,701 467,191 458,36——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0,71%
2 380,40
-17,10
-0,71%
—2 397,502 395,032 412,012 370,64——
Q1 2026 earnings • 5:00 PM today
See details
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
24,81 $
+0,16%
(+0,040) 1D
24,81 $
0,00% (0,00)
After hours
Closed: 4 մյս, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RARE...
Open
24,69 $
High
25,32 $
Low
24,49 $
Mkt. cap
2,44 մլրդ
Avg. vol.
1,96 մլն
Volume
0,00
52-wk high
42,37 $
52-wk low
18,29 $
EPS
-5,83 $
Beta
0,39
Shares outstanding
98,32 մլն
No. of employees
1 հզր
News stories
From sources across the web
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1,37 հզր
Founded2010
HeadquartersNovato, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websiteultragenyx.com
Next call in 14:45:06
Today, 17:00
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (-1,46 est.)USD
Revenue / Estimate
-/ (158,41 մլն est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 թ. մրտ
2025 թ. հնս
2025 թ. սեպ
2025 թ. դեկ
Revenue
139,29 մլն
166,50 մլն
159,93 մլն
207,28 մլն
Cost of goods sold
194,43 մլն
187,74 մլն
244,20 մլն
232,62 մլն
Cost of revenue
194,43 մլն
187,74 մլն
244,20 մլն
232,62 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
87,80 մլն
86,65 մլն
86,62 մլն
87,94 մլն
Operating expense
87,80 մլն
86,65 մլն
86,62 մլն
87,94 մլն
Total operating expenses
282,23 մլն
274,38 մլն
330,82 մլն
320,56 մլն
Operating income
-142,94 մլն
-107,89 մլն
-170,89 մլն
-113,28 մլն
Other non operating income
837,00 հզր
2,14 մլն
-1,04 մլն
-934,00 հզր
EBT including unusual items
-149,77 մլն
-114,00 մլն
-179,54 մլն
-127,69 մլն
EBT excluding unusual items
-149,61 մլն
-114,00 մլն
-180,22 մլն
-127,17 մլն
Income tax expense
1,31 մլն
947,00 հզր
873,00 հզր
870,00 հզր
Effective tax rate
-0,87%
-0,83%
-0,49%
-0,68%
Other operating expenses
-
-
-
-
Net income
-151,08 մլն
-114,95 մլն
-180,41 մլն
-128,56 մլն
Net profit margin
-108,46%
-69,04%
-112,81%
-62,02%
Earnings per share
-1,57
-1,17
-1,81
-1,29
Interest and investment income
6,83 մլն
5,79 մլն
5,86 մլն
6,51 մլն
Interest expense
-14,34 մլն
-14,04 մլն
-14,15 մլն
-19,47 մլն
Net interest expenses
-7,51 մլն
-8,25 մլն
-8,28 մլն
-12,96 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-133,95 մլն
-99,27 մլն
-162,28 մլն
-104,50 մլն
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer